I am convinced that the criminals who have been compressing
I am convinced that the criminals who have been compressing IPIX’s share price (SP) for years realize that grant money is an obvious given, with 2 separate and independent government entities writing peer reviews and sponsoring grant requests. Grant money followed by successful human trials followed by FDA approval of Brilacidin will explode IPIX SP upwards.
What would you do if you were a hedge fund that was exposed with somewhere between 60M to 300M naked IPIX shares (20%-100% x OS per FBI agent post) that you actually have to cover at some point? They are between a rock and a hard place.
If the criminals try to cover their NSS now starting at 16 cents, the millions of share demand on the buy side vs extremely low inventory on the sell side (90% of IPIX investors are long and strong as the shareholder vote proof point), would drive up SP into multiple dollars even prior to the eventual IPIX funding PR announcement. The criminals need to have Longs sell them REAL shares. IMO an average of 80% or so of the current IPIX volume is fake (MMs spoofing volume with mirror trades) so IPIX volume is low due to shortage of real sellers. IMO most Longs will not sell their positions cheaply.
IMO the least costly plan for the criminals is to try to force a low price buyout of IPIX. They have started this campaign with the message board talk of $3-5 buyouts. I personally believe that Leo will laugh off any buyout offers under double digits and Leo has a poison pill in place to prevent any undervalued offers from forcing a buyout.
IMO Leo will NOT sell IPIX anytime soon as Brilacidin is just beginning to prove itself to be a franchise drug with many applications and instances. As funding flows the science of both Brilacidin and Kevetrin will advance and eventually produce massive revenue both directly as well as royalty revenue. A future buyout value of IPIX will be based on 2 major drugs having great market presence, revenue and earnings. At that point in time IPIX will be trading for many dollars per share and will be trading on a legitimate exchange. SP will NOT be based on a multiple of a false denominator of a currently and artificially compressed IPIX SP.
I personally will experience great joy knowing that the criminals will be getting financially crushed with each and every dollar of IPIX SP increase. IPIX value will increase as they continue to execute one milestone after another as the science advances as lifesaving drugs are brought to market.
18
1
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Putting a Roof Over Stockton's Head The talk of the town in Stockton is Health Net stepping up with a $3 million investment. This isn't just dropping loose change in a jar; it's about tackling a mammoth issue—making affordable housing more than just a pipe dream for 75 families. Community-driven, they say. What a cozy way to paint a picture of bridging that brutal gap...
Continue Reading
Strategic Alliances in Real Estate Data When Partner Engineering and Science, Inc. says they're hooking up with the Yardi Independent Consultant Network (ICN), that's not just some boardroom handshake. It's a play that could shake up data services in the real estate game. Look, there's plenty of chatter about digitizing property management, but without killer data, those...
Continue Reading
Revving up efficiency in healthcare usually sounds like pie-in-the-sky talk, but every now and again, an innovation comes along that really stirs the pot. Enter Dyania Health's Synapsis AI, a clinical reasoning AI, teaming with NVIDIA's robust computing infrastructure. They're setting out to make sense of massive amounts of patient data, securely tucked behind a...
Continue Reading
Shockwaves from D-Wave's Earnings Call August wasn't exactly a banner month for D-Wave Quantum, Inc. as their stock went down like a lead balloon following a lackluster earnings report. If you've ever had any skin in the game, you'd know a 9.5% drop isn't just peanuts—it's the equivalent of watching your prized racehorse stumble at the first hurdle. The financials spoke...
Continue Reading
Port Strategy and Financial Implications Terminales Portuarios Euroandinos Paita S.A., nestled in the Peruvian transport sector, has been tight-rope walking through its debt landscape. Announcing a successful consent solicitation on November 13, 2026, they've taken a significant step towards reconfiguring their long-term financing game. This puppet show of paperwork...
Continue Reading
A Different Kind of Game Day Experience Ah, there's nothing quite like the vibrancy of a Texas A&M game day, especially when it's a blackout event. On November 14, fans aren't just getting the good old college football thrills; they're diving headfirst into an extravaganza, courtesy of PenFed Credit Union. You might know them as the go-to credit union for military folks,...
Continue Reading
The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...
Continue Reading
Downturn Despite Strategic Restructuring Today, we're diving into Fly-E Group, Inc. (NASDAQ:FLYE) and the latest shakeup in their financials—spoiler alert, it's riding a downward slope. Quarter two of fiscal 2027 didn't exactly shine a light on profitability. Net revenues slid, dropping to $2.6 million this quarter, down from $3.9 million the previous year. Tack that up...
Continue Reading
Elevating Fitness at RITHM: A New Era Has Begun RD Management just dropped a new ace in Tampa Bay’s hand—LA Fitness ELEVATE at the RITHM at Uptown. They lit up the scene with this 30,000-square-foot beast of a gym, and I’ll tell you, it’s not your standard run-of-the-mill joint. When you toss twelve-and-a-half million bucks into a pot, you're aiming to lure folks...
Continue Reading
Big Moves in the Tech Jungle: FiEE's Comeback Let's chew the fat on FiEE, Inc., a company that's left its hardware-heavy past in the dust and grabbed the bull by the horns with fresh, AI-driven brand tech solutions. We're talking a whopping 382.1% revenue increase. Now, that's not chump change. From barely scraping $2 million last year to raking in $9.6 million just for...
Continue Reading
Top 5 Most Recently Viewed Articles
Cresilon Partners with McCarthy Vet to Distribute VETIGEL Cresilon Inc., an innovative biotechnology firm known for its advanced hemostatic products, has announced a transformative agreement with McCarthy Vet. This collaboration marks a significant step forward as it allows for the distribution of VETIGEL, a groundbreaking hemostatic gel, directly to veterinary surgeons....
Continue Reading
Absci Corporation's Upcoming Financial Reports Absci Corporation (Nasdaq: ABSI), recognized as a pioneer in data-driven generative AI for drug discovery, is gearing up to release important business updates along with financial results for the first quarter of 2025. This report is scheduled to be unveiled subsequent to market close. Key Highlights of the Upcoming Report...
Continue Reading
Borregaard ASA's Second Quarter Results Announcement Borregaard ASA, a renowned name in biochemistry, is set to present its Q2 2025 results. This event will take place on Wednesday, coinciding with July 16, 2025, at 07:00 CEST. As anticipated, a comprehensive stock exchange announcement will follow shortly thereafter. What to Expect from the Presentation The presentation...
Continue Reading
JP Conte's Bet on Brazilian Waste-to-Energy Giant Here's the scoop, folks. Lupine Crest Capital, helmed by none other than JP Conte, just doubled down on their investment in Brazil. This isn't some negligible penny-ante increase, but a hefty infusion of R$70 million—think roughly $14 million in USD—into Orizon Valorização de Resíduos S.A., the notable...
Continue Reading
Hedge funds adjusted their playbooks back then in 2023, net selling equities amid a flurry of options expiry and index rebalancing. The desks were abuzz as they noted slight selling pressure from these funds, yet after the dust settled on that chaotic week, buying picked up noticeably—especially Thursday when it seemed traders found some footing again. Macro Products...
Continue Reading